warning vs. Ayala Center, Makati
security lapses at entrances to: Glorietta 5, Greenbelt 5 to Greenbelt 1,, Glorietta 3, Park Square 1, SM building, Landmark building, Rustans building.
Defective doorknob at door of washroom of what was identified as Glorietta 3 resulted in my being unable, for several minutes, to leave said room.
Regarding said security lapses, when I entered said areas, the guards at entrances to said areas: did not inspect the insides of my luggage; did not use
a metal detector to scan said luggage; did not use a bomb sniffing animal to smell said luggage. Said luggage is large enough to contain hand grenades.

I entered Glorietta 5 on December 6, 2010. The guard at the entrance (opposite the Rustan’s building) to said Glorietta 5: did not inspect the inside of
my luggage; did not scan said luggage with a metal detector; did not have a bomb sniffing animal smell said luggage. Said luggage was large enough to
contain grenades. On said date, I submitted a written complaint vs. said security lapse. Said written complaint was received at what was identified as
the concierge within said building. The person who received said written complaint identified herself/himself as Crystal Joice. Up to
June 18, 2011, neither the building administrator of said building nor anyone identified as with Ayala Center Makati or with Ayala Land Corporation has
contacted me regarding said security lapse.


FDA Warns of MI, PAD Risk With Chantix
By Peggy Peck, Executive Editor, MedPage Today
Published: June 16, 2011


WASHINGTON -- The FDA warned today that smokers with a history of heart attack or stroke who use the smoking cessation drug varenicline (Chantix) may increase their risk of a second heart attack or new onset peripheral vascular disease.

The agency said an additional warning will be added to the drug's label and prescribing information describing a small, but measurable increase in the risk of cardiovascular events including nonfatal myocardial infarction, angina, and need for coronary revascularization.

Additionally, the label will warn that use of varenicline may increase the risk for a "new diagnosis of peripheral vascular disease or admission for a procedure for the treatment of peripheral vascular disease" among persons with a history of cardiovascular disease.

In its announcement, the FDA noted that smoking significantly increases the risk of cardiovascular events, so it advised physicians and patients to weigh the known benefits of varenicline treatment "against its potential risks when deciding to use the drug in smokers with cardiovascular disease."

The FDA decided to add the warnings after it reviewed data from a randomized, double-blind, placebo-controlled study of 700 smokers with a history of cardiovascular disease who were treated with varenicline or placebo.

The FDA said it was "continuing to evaluate the cardiovascular safety of Chantix" and had ordered the drug's maker to conduct a meta-analysis of data from all varenicline studies as part of an ongoing review of the drug's cardiovascular safety.

Concerns about cardiovascular safety come on top of previous reports of increased risk of suicidal ideation association with varenicline, which is marketed by Pfizer.



web sites with free, useful information:

http://www.eol.org/
Encyclopedia of Life web site

http://www.asha.org/
American Speech-Language-Hearing Association

http://www.consumeraction.gov/
Consumer Action Web site

http://consumerworld.org/
consumerworld web site

http://www.kiplinger.com/
kiplinger web site

http://digestive.niddk.nih.gov/
National Digestive Diseases Information Clearinghouse web site


http://www.sleepfoundation.org/
National Sleep Foundation web site


http://www.ftc.gov/
U. S. Federal Trade Commission web site

http://www.askmen.com/
askmen web site